Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer
Clinical trial NCT05241340 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05241340
- Sponsor
- The Methodist Hospital Research Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-15
- Primary completion
- 2025-08-01
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.